Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases

In 2018, Baricitinibwas approved by the Food and Drig Administration (FDA) for the treatment of rheumatoid arthritis. Baricitinibexerts its action by targeting Janus kinases(JAK). In this study, we describe the necessary steps for preparing the drug using two alternative routes.